Clinical trials: Newly Diagnosed
Safety and Efficacy
Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL
ENKTL is a highly aggressive NHL with a higher incidence in Asia. L-asparaginase containing chemotherapy regimens are the standard first-line treatment with apparently toxicities.
- Trial name
- NCT04994210
- Testing
- Sintilimab, Chidamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
DLBCL - Diffuse Large B Cell Lymphoma, Pirtobrutinib
Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL
This is a single-arm, open-label, multicenter clinical study evaluating the efficacy and safety of pirtobrutinib combined with Pola-R-CHP in previously untreated Non-GCB DLBCL.
- Trial name
- NCT07744724
- Testing
- Pirtobrutinib+Pola-R-CHP
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Changzhou No.2 People's Hospital
NSCLC, Brain Metastases
A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)
Almonertinib is a three-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), which has shown competitive potential in the second-line treatment against first-generation TKIs.
- Conditions
- NSCLC, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- NCT04778800
- Testing
- almonertinib, LM-first line treatment, LM-second line treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Diffuse Large B-cell Lymphoma
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
This is an open-label, randomized, multicentre study to evaluate safety and preliminary efficacy of the human anti-CD19 antibody Tafasitamab in addition to R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine…
- Trial name
- NCT04134936
- Testing
- Tafasitamab, Tafasitamab plus lenalidomide
- Where
- 70 sites in United States, Austria and 7 more
- Volunteers
- 66 people
- Sponsor
- MorphoSys AG
Sarcoma
Combination Chemotherapy in Treating Patients Undergoing Surgery for Newly Diagnosed High-Grade Osteosarcoma
RATIONALE: Drugs used in chemotherapy, such as ifosfamide, methotrexate, cisplatin, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00645632
- Testing
- cisplatin, doxorubicin hydrochloride, ifosfamide
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Primary Central Nervous System Lymphoma (PCNSL), Non Hodgkin Lymphoma (NHL)
High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)
This is a phase Ⅱ clinical study of Zanubrutinib(Z) in combination with methotrexate (M) and thiotepa(T) in treating newly diagnosed primary CNS lymphoma (PCNSL).
- Trial name
- NCT06646211
- Testing
- Zanubrutinib , Thiotepa, Methotrexate , Thiotepa and Zanubrutinib, ASCT±Zanubrutinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Glioblastoma
Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma
In summary, the overall prognosis of glioblastoma (GBM) patients remains poor. Although clinical gains have been achieved in the past, these have been modest, with a majority of patients succumbing to local disease progression…
- Trial name
- NCT02394665
- Testing
- Intensity Modulated Radiation Therapy, Temozolomide, Functional Assessment of Cancer Therapy-Brain (FACT-Br)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Miami
Peripheral T Cell Lymphoma Unspecified, Anaplastic Large Cell Lymphoma, ALK-negative
RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas
The urgent need for new effective therapy for T-cell lymphoma patients and promising results observed so far in trials with RAD001(everolimus, mTOR inhibitor) strongly warrants the investigation of RAD001 combined with CHOP as a…
- Conditions
- Peripheral T Cell Lymphoma Unspecified, Anaplastic Large Cell Lymphoma, ALK-negative, Angioimmunoblastic T Cell Lymphoma, Cutaneous T Cell Lymphoma
- Trial name
- RADCHOP (NCT01198665)
- Testing
- RAD001 (Everolimus)
- Where
- 5 sites in South Korea
- Volunteers
- 46 people
- Sponsor
- Samsung Medical Center
Type 1 Diabetes
Etanercept in New Onset Type 1 Diabetes
The investigators hypothesized that the administration of Etanercept to children newly diagnosed with T1DM may be able to interdict the progression of T1DM.
- Trial name
- NCT00730392
- Testing
- Etanercept
- Volunteers
- 18 people
- Sponsor
- State University of New York at Buffalo
Dasatinib, BCR-ABL
Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP
The purpose of this study is to explore the efficacy and safety of dasatinib 70 mg once daily as first line therapy in patients with early chronic phase (CP) chronic myeloid leukemia (CML).
- Conditions
- Dasatinib, BCR-ABL, Chronic Myeloid Leukemia
- Trial name
- NCT04155411
- Testing
- Dasatinib
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Shenzhen Second People's Hospital
Glioblastoma, Glioblastoma, WHO Grade IV
Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)
Glioblastoma multiforme (GBM) is the most common and deadliest primary malignant neoplasm of the central nervous system in adults.
- Trial name
- 2-THE-TOP (NCT03405792)
- Testing
- Temozolomide (TMZ), Optune System, Pembrolizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Florida
Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
This partially randomized phase II trial studies how well brentuximab vedotin or crizotinib and combination chemotherapy works in treating patients with newly diagnosed stage II-IV anaplastic large cell lymphoma.
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
- Trial name
- NCT01979536
- Testing
- Brentuximab Vedotin, Crizotinib, Cyclophosphamide
- Where
- 154 sites in United States
- Volunteers
- 137 people
- Sponsor
- National Cancer Institute (NCI)
Pulmonary Tuberculosis (TB)
Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB
This is the first trial in a series of clinical trials that aim to bring the concept of high dose rifampicin beyond phase II of clinical development.
- Trial name
- HR1 (NCT01392911)
- Testing
- Rifampicin
- Where
- 2 sites in South Africa
- Volunteers
- 128 people
- Sponsor
- Radboud University Medical Center
Chronic Phase-Chronic Myeloid Leukemia
Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients
The combination of bosutinib plus atezolizumab in first line treatment in newly diagnosis chronic-phase Chronic Myeloid Leukemia (CML) patients could potentially increase molecular responses and therefore treatment…
- Trial name
- NCT04793399
- Testing
- Bosutinib 400 MG Monotherapy, Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection
- Where
- 2 sites in Spain
- Volunteers
- 9 people
- Sponsor
- Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica
AML, Adult
Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients
All patients receiving induction, consolidation and salvage chemotherapy, and autologous or allogeneic stem cell transplantation according to a strategy defined in the GIMEMA AML1310 protocol will be prospectively monitored for…
- Trial name
- AML1411 (NCT01570465)
- Testing
- Observation
- Where
- 46 sites in Italy
- Volunteers
- 144 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Glioblastoma
Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients
The prognosis of patients with newly diagnosed glioblastoma is dismal despite recent therapeutic improvements Using standard therapy with temozolomide (TMZ) and radiotherapy (60 Gy), the median overall survival time (mOS) is 14.6…
- Trial name
- CeTeG (NCT01149109)
- Testing
- Temozolomide and lomustine, Temozolomide
- Where
- 12 sites in Germany
- Volunteers
- 141 people
- Sponsor
- University Hospital, Bonn
AL Amyloidosis
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD…
- Trial name
- NCT06022939
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection
- Where
- 117 sites in United States
- Volunteers
- 338 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
Randomized Trial of Suicide Gene Therapy and Prostate Cancer
This is a randomized, controlled trial that will test the hypothesis that replication-competent adenovirus-mediated suicide gene therapy in combination with 80 Gy intensity modulated radiotherapy (IRMT)will improve freedom from…
- Trial name
- ReCAP (NCT00583492)
- Testing
- Ad5-yCD/mutTKSR39rep-ADP, IMRT
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Henry Ford Health System
Lymphoma
Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003311
- Testing
- filgrastim, cyclophosphamide, cytarabine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
MUK Nine b: OPTIMUM Treatment Protocol
To determine whether a combination of four novel agents bortezomib(Velcade), lenalidomide (Revlimid), Daratumumab (Darzalex) \& dexamethasone in combination with low-dose cyclophosphamide is sufficiently active in a high risk…
- Trial name
- MUKnineb (NCT03188172)
- Testing
- Cyclophosphamide, Bortezomib, Lenalidomide
- Where
- 21 sites in United Kingdom
- Volunteers
- 95 people
- Sponsor
- University of Leeds